FDA Clearance Paves Way for Quantum BioPharma's Lucid-MS Phase 2 Trial in Multiple Sclerosis

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for Lucid-MS, allowing the company to proceed with a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis. The milestone positions Lucid-MS as a potential first-in-class therapy that takes a fundamentally different approach to treating MS by targeting the underlying demyelination process rather than suppressing the immune system. This distinction could be significant for patients who do not respond adequately to existing immunomodulatory treatments or who experience debilitating side effects from long-term immune suppression.

Lucid-MS is a patented, non-covalent inhibitor of peptidyl arginine deiminase 2, an enzyme implicated in myelin degradation. By directly preventing and potentially reversing myelin damage, the drug candidate aims to address the root cause of MS progression. Preclinical models have shown that Lucid-MS can prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. If the phase 2 trial confirms these effects in humans, Lucid-MS could become a complementary or alternative therapy for the millions of people worldwide living with MS.

The FDA's clearance of the IND application is a critical regulatory step that enables Quantum BioPharma to initiate the trial. The company's research collaboration with Massachusetts General Hospital and Harvard Medical School involving the [¹⁸F]3F4AP PET imaging tracer further strengthens its scientific foundation. This tracer is being evaluated as a method to visualize and measure demyelination, which could provide a valuable biomarker for assessing treatment response and accelerate drug development. The ability to objectively measure myelin repair would be a major advance for MS research and could help streamline future clinical trials.

Quantum BioPharma's progress comes amid a broader wave of innovation in biopharmaceuticals, with companies like Novartis AG (NYSE: NVS) receiving FDA approval for Pluvicto(R) in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer. Merck & Co. Inc. (NYSE: MRK) has had its supplemental Biologics License Application for ENFLONSIA(TM) accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease. TG Therapeutics Inc. (NASDAQ: TGTX) initiated a phase 2 trial of BRIUMVI(R) in adults with treatment-resistant schizophrenia, and Bristol-Myers Squibb Company (NYSE: BMY) reported positive phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma. These developments underscore the industry's collective push to address unmet medical needs, and Quantum BioPharma's advancement of Lucid-MS places it among these innovative efforts.

For Quantum BioPharma, the path to phase 2 represents a significant value inflection point. Successful trial results could lead to partnerships, licensing deals, or accelerated development, ultimately benefiting shareholders and patients alike. The company retains full rights to Lucid-MS and is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders. With the FDA clearance in hand, Quantum BioPharma is poised to advance Lucid-MS into the clinic and potentially transform the treatment landscape for multiple sclerosis. To view the full press release, visit https://ibn.fm/lCey9. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.